We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00837252
First Posted: February 5, 2009
Last Update Posted: September 26, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Eye Institute (NEI) )
Results First Submitted: April 21, 2011  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Retinal Disease
Intervention: Drug: Finasteride

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Finasteride All five study participants (all of whom were diagnosed with chronic CSC) were administered a 5mg oral dose of finasteride daily for three months. After three months, the finasteride was withheld and the participants were observed for another three months.

Participant Flow:   Overall Study
    Finasteride
STARTED   5 
COMPLETED   5 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Finasteride No text entered.

Baseline Measures
   Finasteride 
Overall Participants Analyzed 
[Units: Participants]
 5 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   5 
>=65 years   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 50  (10.4) 
Gender 
[Units: Participants]
 
Female   0 
Male   5 
Region of Enrollment 
[Units: Participants]
 
United States   5 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Visual Acuity at Month 3 Compared to Baseline.   [ Time Frame: 3 months ]

2.  Secondary:   Change in Visual Acuity at Month 6 Compared to Baseline   [ Time Frame: 6 months ]

3.  Secondary:   Change in Center-Subfield Macular Thickness at Month 3 Compared to Baseline   [ Time Frame: 3 months ]

4.  Secondary:   Change in Center-Subfield Macular Thickness at Month 6 Compared to Baseline   [ Time Frame: 6 months ]

5.  Secondary:   Change in Subretinal Fluid Volume at Month 3 Compared to Baseline   [ Time Frame: 3 Months ]

6.  Secondary:   Change in Subretinal Fluid Volume at Month 6 Compared to Baseline   [ Time Frame: 6 Months ]

7.  Secondary:   Change in Serum Dihydrotestosterone (DHT) Concentration at Month 3 Compared to Baseline   [ Time Frame: 3 Months ]

8.  Secondary:   Change in Serum Dihydrotestosterone (DHT) Concentration at Month 6 Compared to Baseline   [ Time Frame: 6 Months ]

9.  Secondary:   Change in Serum Testosterone Level at Month 3 Compared to Baseline   [ Time Frame: 3 Months ]

10.  Secondary:   Change in Serum Testosterone Level at Month 6 Compared to Baseline   [ Time Frame: 6 Months ]

11.  Secondary:   Change in Urinary Cortisol Level at Month 3 Compared to Baseline   [ Time Frame: 3 Months ]

12.  Secondary:   Change in Urinary Cortisol Level at Month 6 Compared to Baseline   [ Time Frame: 6 Months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Catherine M. Meyerle, MD
Organization: National Eye Institute
phone: 301-435-7821
e-mail: meyerlec@nei.nih.gov


Publications of Results:
Other Publications:

Responsible Party: National Institutes of Health Clinical Center (CC) ( National Eye Institute (NEI) )
ClinicalTrials.gov Identifier: NCT00837252     History of Changes
Other Study ID Numbers: 090075
09-EI-0075 ( Other Identifier: National Eye Institute IRB )
First Submitted: February 4, 2009
First Posted: February 5, 2009
Results First Submitted: April 21, 2011
Results First Posted: May 16, 2011
Last Update Posted: September 26, 2016